Workflow
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,
Jazz PharmaceuticalsJazz Pharmaceuticals(US:JAZZ) ZACKSยท2025-03-05 21:10

Core Insights - The medical sector is gaining investor interest amid economic uncertainty and stock market volatility, with several healthcare stocks achieving Zacks Rank 1 (Strong Buy) status [1] Company Summaries - Jazz Pharmaceuticals (JAZZ): A specialty biopharmaceutical company focusing on neuroscience and oncology, with projected total sales exceeding $4 billion and a 5% increase in fiscal 2025 and FY26. Earnings per share (EPS) are expected to rise 10% this year to $23.12, up from $20.90 in 2024, with a further 2% increase projected for FY26 [2][3] - Pacira BioSciences (PCRX): Another specialty biopharmaceutical company, emphasizing proprietary products for hospitals and ambulatory surgery centers. Trading at $23, PCRX has a forward earnings multiple of 6.5X, with EPS projected to increase 12% in FY25 and another 20% next year to $4.30 [5][6] - Option Care Health (OPCH): A provider of infusion and home care management solutions, trading at 52-week highs of $34. The stock has increased by 50% in 2025 and trades at a reasonable 20X forward earnings multiple, with consistent performance exceeding Zacks EPS Consensus for 10 consecutive quarters [8][9] Market Performance - Jazz Pharmaceuticals' stock trades at 6X forward earnings, significantly lower than the industry average of 19.3X and the S&P 500 at 21.8X, indicating a potential value opportunity [4] - Pacira BioSciences has shown steady top-line growth, soaring over 20% year-to-date and trading under 2X sales [6] - Option Care Health has been one of the top market performers this year, reflecting strong growth and a favorable Zacks Style Scores grade for Value, Growth, and Momentum [9] Earnings Estimates - Jazz Pharmaceuticals has a Zacks Consensus Estimate for EPS of $23.12 for the current year, with a year-over-year growth estimate of 10.62% [4] - Pacira BioSciences is projected to have a 12% increase in EPS for FY25, with a further 20% increase expected next year [6] - Option Care Health's strong performance is supported by consistent earnings estimates, contributing to its strong buy rating [11]